Satellos is a regenerative medicine company developing novel therapeutics that aim to change the way we treat degenerative muscle diseases. Based on twenty years of groundbreaking muscle stem discoveries by our founder and CSO, Satellos has created a proprietary technology platform, MyoReGenX™. Leveraging MyoReGenX™, we identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions to overcome them. Our lead program is focused on the development of a first-in-class therapeutic capable of correcting the impaired muscle regenerative process in Duchenne, with potential to improve the quality and duration of patients’ lives.
Satellos Bioscience Inc. was founded in 2018 by biotechnology entrepreneurs Mr. Frank Gleeson and Dr. Michael Rudnicki, PhD, OC, FRS in partnership with Bloom Burton & Co., Canada’s largest specialty biotechnology advisors and bankers. Based on significant scientific progress since our inception, the company took the strategic decision to access the public capital markets to accelerate development and fuel future growth. In 2021, Satellos executed a reverse takeover of iCo Therapeutics Inc., undertook a concurrent capital raise and began trading on the TSX-V under the ticker “MSCL”.